Moxidectin combination therapies for lymphatic filariasis: an open-label, observer-masked, randomised controlled trial.

Journal: The Lancet. Infectious diseases
Published Date: May 5, 2025

Abstract

BACKGROUND: Lymphatic filariasis caused by Wuchereria bancrofti causes hydroceles and lymphedema in millions of individuals worldwide. Annual mass drug administration of ivermectin plus albendazole (IA) temporarily clears microfilariae from the blood of infected individuals and is used in Africa to reduce W bancrofti transmission. This study aimed to investigate whether moxidectin combination therapies are superior to ivermectin combination therapies for clearance of W bancrofti microfilaremia.

Authors

  • Guibehi Benjamin Koudou
    Centre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, Côte d'Ivoire; Unité de Formation Recherches des Sciences de la Nature, Université Nangui Abrogoua, Abidjan, Côte d'Ivoire.
  • Catherine M Bjerum
    Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
  • Foungoye Allassane Ouattara
    Centre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, Côte d'Ivoire; Unité de Formation Recherches des Sciences de la Nature, Université Nangui Abrogoua, Abidjan, Côte d'Ivoire.
  • Toki Pascal Gabo
    Centre Hospitalier Régional d'Agboville, Agboville, Côte d'Ivoire.
  • Charles W Goss
    Institute for Informatics, Data Science, and Biostatistics, Washington University School of Medicine, St Louis, MO, USA.
  • Daphne Lew
    Institute for Informatics, Data Science, and Biostatistics, Washington University School of Medicine, St Louis, MO, USA.
  • N'Goran N Dje
    Programme National de la Lutte Contre Les Maladies Tropicales Négligées à Chimiothérapie Préventive (PNLMTN-CP), Abidjan, Côte d'Ivoire.
  • Christopher L King
    Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, OH, USA; Veterans Affairs Research Service, Cleveland Veterans Affairs Medical Center, Cleveland, OH, USA.
  • Peter U Fischer
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, MO, USA.
  • Gary J Weil
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, MO, USA.
  • Philip J Budge
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, MO, USA. Electronic address: pbudge@wustl.edu.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals